New Zealand-based Aether Pacific Pharmaceuticals has struck another deal to distribute and sell its range of medicinal cannabis products in Australia.

Under memorandums of understanding (MOUs) with Alliance Healthcare Australia, the businesses will form a 50/50 joint venture to open a pharmacy in NZ that will dispense prescriptions written by Aether Pacific’s telehealth network and by doctors its two physical locations – called The Pain Clinic – in Christchurch and Nelson.

The pharmacy will also be situated in Christchurch and is expected to open by the end of March.

A second agreement will enable Alliance to market, sell and distribute Aether’s dried cannabis flower in Australia, with the medicine either white labelled or sold under Aether’s Medical Kiwi brand.

It is the third distribution agreement Aether has signed in recent months, following deals inked with Novachem in September and MediCann Health.

The relationship with Alliance will begin “shortly”, Aether said, with the delivery of 10g jars of cannabis strains grown by its cultivation division, Medical Kiwi.

The products will have THC content of between 17% and 25%.

Aether Pacific Pharmaceuticals chairman Aldo Miccio said the partnership could unlock “significant sales growth” in the Australian market.

“We are pleased to work with Alliance Healthcare Australia to foster these distribution pathways in a strategic way which leverages the respective strengths of both companies,” he said.

Aether Pacific CEO Aldo Miccio

“Within the broader growth of the medicinal cannabis industry both in Australia and globally, we are focused on bringing an innovative partnership approach to capitalise on the sector’s momentum.

“In that context, the MOUs provide the company with a significantly expanded addressable market while also further strengthening our working relationship with Alliance.”

Alliance Healthcare Australia chief executive Brendon Rose added: “We are excited to be working with the Aether Pacific team on these strategic distribution initiatives, with the aim of providing Australian consumers with access to best-in-class medicinal cannabis products grown to the highest quality standards in New Zealand.

“The MOUs establish the framework for Alliance to take immediate delivery of premium cannabis flower for distribution in the Australian market, while also setting up a longer-term JV operating structure for a holistic farm-to-patient distribution model that aligns with the incentives of all stakeholders and, importantly, our customers.”

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment